H. Dietrich

No ORCID on file · 8 papers in corpus · active 1999-2015

Study types

  • article 8

Condition tags

  • dysmenorrhea 2
  • die_deep_infiltrating 1
article 2015
Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days
·doi:10.3109/09513590.2015.1024220

BACKGROUND: Concern and controversy characterize nowadays the use of hormone therapy for management of patients with menopausal complaints. This observational non-interventional study examined the use of a marketed oral formulation containi…

article 2006
Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg of ethinyl estradiol and 2 mg of dienogest
·doi:10.1016/j.fertnstert.2005.11.052
article 2005
Fertilität nach Absetzten eines oralen Kontrazeptivums mit 30µg Ethinylestradiol und 2mg Dienogest
·doi:10.1055/s-2005-870731

Fragestellung: Retrospektiven Untersuchungen haben gezeigt, dass die Fertilität nach dem Absetzen eines oralen Kontrazeptivums (OC) für die Dauer von bis zu 2 Jahren negativ beeinflusst werden kann. Bei repräsentativen Umfragen nahmen in Dr…

article 2000
The effects of Valette on skin and hair: a post-marketing surveillance study.

The effects of Valette--an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg--on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecological practice…

article 2000
THE EFFECTS OF VALETTE® ON SKIN AND HAIR: A POST‐MARKETING SURVEILLANCE STUDY
·doi:10.1111/j.1742-1241.2000.tb11855.x

SUMMARY The effects of Valette ® ‐ an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg ‐ on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecologi…

article 1999
Effects of the dienogest-containing oral contraceptive Valette on skin and hair Results of a postmarketing surveillance study
article 1999
The efficacy and tolerability of Valette®: a postmarketing surveillance study
·doi:10.3109/13625189909040810

Objectives and methods A postmarketing survey was carried out to determine the efficacy and tolerability of Valette® (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice.Results Valette had excellent contracepti…

article 1999
The efficacy and tolerability of Valette®: a postmarketing surveillance study
·doi:10.1080/13625189909040810

OBJECTIVES AND METHODS: A postmarketing survey was carried out to determine the efficacy and tolerability of Valette (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice. RESULTS: Valette had excellent contracep…